Pulmonary Delivery of Biological Drugs
| العنوان: | Pulmonary Delivery of Biological Drugs |
|---|---|
| المؤلفون: | Harry W. Pan, Driton Vllasaliu, Jenny K.W. Lam, Wanling Liang |
| المصدر: | Pharmaceutics, Vol 12, Iss 1025, p 1025 (2020) Pharmaceutics |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Drug, medicine.medical_specialty, aerosol, media_common.quotation_subject, Pharmaceutical Science, lcsh:RS1-441, 02 engineering and technology, Review, Cystic fibrosis, lung, Biological drugs, lcsh:Pharmacy and materia medica, 03 medical and health sciences, Route of administration, medicine, Intensive care medicine, 030304 developmental biology, media_common, 0303 health sciences, inhalation, Lung, therapeutic proteins, Inhalation, business.industry, 021001 nanoscience & nanotechnology, medicine.disease, Bioavailability, medicine.anatomical_structure, Drug delivery, monoclonal antibodies, 0210 nano-technology, business |
| الوصف: | In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery. The main challenges in the formulation and inhalation devices are discussed, together with the possible strategies that can be applied to address these challenges. Current clinical developments in inhaled biological drugs for both local and systemic applications are also discussed to provide an insight for further research. |
| اللغة: | English |
| تدمد: | 1999-4923 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4aa9985bea56af163cd5824b153e555Test https://www.mdpi.com/1999-4923/12/11/1025Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c4aa9985bea56af163cd5824b153e555 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19994923 |
|---|